SWOG clinical trial number

SWOG-9455

A Phase II Study of 5-FU Infusion and Alpha Interferon for Treatment of Advanced or Recurrent Metastatic Adenocarcinoma of the Bladder

Closed

Phase

Accrual

8%

Abbreviated Title

Advanced Bladder

Activated

11/15/1996

Closed

12/01/1998

Research committees

Genitourinary Cancer

Other Clinical Trials

SWOG Clinical Trial Number

S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)

Genitourinary Cancer

Activated

08/14/2023

Accrual

2%

Open

Phase

SWOG Clinical Trial Number

S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

Research Committee(s)

Genitourinary Cancer

Activated

09/19/2022

Accrual

8%

Open

Phase

SWOG Clinical Trial Number

CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Research Committee(s)

Genitourinary Cancer

Activated

05/01/2021

Open

Phase